Immunotherapy targeting the PD-1–PD-L1 axis yielded good results in treating different immunologically ‘‘hot’’ tumors. A phase II study revealed good therapeutic activity of pembroli-zumab in selected prostatic carcinoma (PC)-patients. We performed a systematic literature review (PRISMA guidelines), which analyzes the immunohistochemical expression of PD-L1 in human PC samples and highlights the pre-analytical and interpretation variables. Interestingly, 29% acinar PCs, 7% ductal PCs, and 46% neuroendocrine carcinomas/tumors were PD-L1+ on immunohisto-chemistry. Different scoring methods or cut-off criteria were applied on variable specimen-types, evaluating tumors showing different clinic-pathologic features. The positivity rate of different PD-L1 antibody clones in tumor cells ranged from 3% (SP142) to 50% (ABM4E54), excluding the single case tested for RM-320. The most tested clone was E1L3N, followed by 22C3 (most used for pem-brolizumab eligibility), SP263, SP142, and 28-8, which gave the positivity rates of 35%, 11–41% (de-pending on different scoring systems), 6%, 3%, and 15%, respectively. Other clones were tested in <200 cases. The PD-L1 positivity rate was usually higher in tumors than benign tissues. It was higher in non-tissue microarray specimens (41–50% vs. 15%), as PC cells frequently showed heterogenous or focal PD-L1-staining. PD-L1 was expressed by immune or stromal cells in 12% and 69% cases, respectively. Tumor heterogeneity, inter-institutional preanalytics, and inter-observer interpretation variability may account for result biases.

What do we have to know about pd-l1 expression in prostate cancer? A systematic literature review. part 1: Focus on immunohistochemical results with discussion of pre-analytical and interpretation variables / Palicelli, A.; Bonacini, M.; Croci, S.; Magi-Galluzzi, C.; Canete-Portillo, S.; Chaux, A.; Bisagni, A.; Zanetti, E.; De Biase, D.; Melli, B.; Sanguedolce, F.; Ragazzi, M.; Bonasoni, M. P.; Soriano, A.; Ascani, S.; Zizzo, M.; Ruiz, C. C.; De Leo, A.; Giordano, G.; Landriscina, M.; Carrieri, G.; Cormio, L.; Berney, D. M.; Athanazio, D.; Gandhi, J.; Cavazza, A.; Santandrea, G.; Tafuni, A.; Zanelli, M.. - In: CELLS. - ISSN 2073-4409. - 10:11(2021), pp. 3166-3191. [10.3390/cells10113166]

What do we have to know about pd-l1 expression in prostate cancer? A systematic literature review. part 1: Focus on immunohistochemical results with discussion of pre-analytical and interpretation variables

Melli B.;Ragazzi M.;Zizzo M.;Landriscina M.;Santandrea G.;
2021-01-01

Abstract

Immunotherapy targeting the PD-1–PD-L1 axis yielded good results in treating different immunologically ‘‘hot’’ tumors. A phase II study revealed good therapeutic activity of pembroli-zumab in selected prostatic carcinoma (PC)-patients. We performed a systematic literature review (PRISMA guidelines), which analyzes the immunohistochemical expression of PD-L1 in human PC samples and highlights the pre-analytical and interpretation variables. Interestingly, 29% acinar PCs, 7% ductal PCs, and 46% neuroendocrine carcinomas/tumors were PD-L1+ on immunohisto-chemistry. Different scoring methods or cut-off criteria were applied on variable specimen-types, evaluating tumors showing different clinic-pathologic features. The positivity rate of different PD-L1 antibody clones in tumor cells ranged from 3% (SP142) to 50% (ABM4E54), excluding the single case tested for RM-320. The most tested clone was E1L3N, followed by 22C3 (most used for pem-brolizumab eligibility), SP263, SP142, and 28-8, which gave the positivity rates of 35%, 11–41% (de-pending on different scoring systems), 6%, 3%, and 15%, respectively. Other clones were tested in <200 cases. The PD-L1 positivity rate was usually higher in tumors than benign tissues. It was higher in non-tissue microarray specimens (41–50% vs. 15%), as PC cells frequently showed heterogenous or focal PD-L1-staining. PD-L1 was expressed by immune or stromal cells in 12% and 69% cases, respectively. Tumor heterogeneity, inter-institutional preanalytics, and inter-observer interpretation variability may account for result biases.
2021
10
11
3166
3191
What do we have to know about pd-l1 expression in prostate cancer? A systematic literature review. part 1: Focus on immunohistochemical results with discussion of pre-analytical and interpretation variables / Palicelli, A.; Bonacini, M.; Croci, S.; Magi-Galluzzi, C.; Canete-Portillo, S.; Chaux, A.; Bisagni, A.; Zanetti, E.; De Biase, D.; Melli, B.; Sanguedolce, F.; Ragazzi, M.; Bonasoni, M. P.; Soriano, A.; Ascani, S.; Zizzo, M.; Ruiz, C. C.; De Leo, A.; Giordano, G.; Landriscina, M.; Carrieri, G.; Cormio, L.; Berney, D. M.; Athanazio, D.; Gandhi, J.; Cavazza, A.; Santandrea, G.; Tafuni, A.; Zanelli, M.. - In: CELLS. - ISSN 2073-4409. - 10:11(2021), pp. 3166-3191. [10.3390/cells10113166]
Palicelli, A.; Bonacini, M.; Croci, S.; Magi-Galluzzi, C.; Canete-Portillo, S.; Chaux, A.; Bisagni, A.; Zanetti, E.; De Biase, D.; Melli, B.; Sanguedolce, F.; Ragazzi, M.; Bonasoni, M. P.; Soriano, A.; Ascani, S.; Zizzo, M.; Ruiz, C. C.; De Leo, A.; Giordano, G.; Landriscina, M.; Carrieri, G.; Cormio, L.; Berney, D. M.; Athanazio, D.; Gandhi, J.; Cavazza, A.; Santandrea, G.; Tafuni, A.; Zanelli, M.
File in questo prodotto:
File Dimensione Formato  
PDL1 part1_Cells 2021.pdf

Open access

Tipologia: Versione pubblicata dall'editore
Dimensione 1.06 MB
Formato Adobe PDF
1.06 MB Adobe PDF Visualizza/Apri
Pubblicazioni consigliate

Licenza Creative Commons
I metadati presenti in IRIS UNIMORE sono rilasciati con licenza Creative Commons CC0 1.0 Universal, mentre i file delle pubblicazioni sono rilasciati con licenza Attribuzione 4.0 Internazionale (CC BY 4.0), salvo diversa indicazione.
In caso di violazione di copyright, contattare Supporto Iris

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11380/1302926
Citazioni
  • ???jsp.display-item.citation.pmc??? 9
  • Scopus 12
  • ???jsp.display-item.citation.isi??? 13
social impact